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Introduction:
The house always wins.

A common saying about casinos, but

it’s not just a saying, it’s a necessity.

If the house lost,

then sooner or later the casino would go out of business.
money coming in must always exceed the money going out.

The
This

same concept can be applied to insurance companies, since
insurance is similar to a very large scale casino.

The way it

works is that a person pays their premium each month which is
akin to placing down a bet each month.

The bet is whether or

not you will either get in a car accident for auto insurance,
get sick for health insurance, have damage done to you house for
home insurance, and so on.

So what happens if the amount you

pay out begins to increase faster than the amount of money
coming into the business?

The answer is that you run the risk

of becoming insolvent and going bankrupt; for an insurance
company, this can be very bad news for all those depending on
1

the coverage.

Another similarity to casinos is that the largest

payouts go to a very small percentage of all the players.

In

casinos, it’s the one who wins the jackpot. In insurance it’s
the one who is injured the most.

The simplest solution to

trying to prevent insolvency would be to eliminate those taking
out the most money. This is where health insurance is far
different than casinos and all other forms of insurance.
It’s quite possible to go through life without ever getting
in a car accident requiring filing of a claim such that your
insurance carrier may never have to make a payout. The same
cannot be said about getting injured or sick.

Even if it’s

merely by old age, everyone will eventually need health care.
Not only that, the health of people is valued greatly in our
society.

This can be seen in the fact that many countries have

their health care run by the government for the benefit of all,
and recently in the United States of America the passing of the
Patient Protection and Affordable Health Care Act.
The true challenge lies in trying to strike a balance
between two different objectives of Health Insurance.

The first

is the objective of sustainability and profit, which is the
insurance companies need to keep the amount of money being paid
in greater than that of the money they must pay out to those
insured.

The second objective is providing affordable and
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quality care given to patients.
maintaining cost.

The common element here is in

One of the major cost areas in health

insurance is prescription drugs.
The consumption of prescription drugs is increasing at an
alarming rate with the rate at which new and more expensive
drugs are coming out.

The Health Insurance industry needs to

plan on how to manage these costs while still allowing for the
best care to patients.
This paper will show the current method in place to combat
the rising consumption of prescription drugs, and how this
current method marginalizes those who need the most expensive
drugs for the sake of containing costs.
There are changes that can be taken to effectively cut
cost, and some of these methods can lower cost without singling
out any one group of prescription drugs consumers.

The Problem:
Left to their own market forces the cost of prescriptions
drugs increases exponentially.1 During a 5 year period between
1995 and 2000 the money spent on prescription drugs by Americans
doubled from 60 to roughly 120 billion dollars.1 Now before
trying to make an effort to solve the problem it’s important to
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understand it first.

In the article, Understanding Health Care

Cost Drivers by the National Institute of Health Policy it
discusses many of the cost drivers.
The first reason offered is our ever increasing elderly
population.2

The following graph shows the amount of drugs used

by each age group.4

As seen in the graph, as people get older the odds of them being
on at least 1 prescription drug increases to roughly 90%.4
The next reason offered is Direct-to-consumer advertising.2
This refers to the advertising shown on television, radio, and
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the web.2 The stringent “warning labels” are much more lax when
it comes to these ads as of the FDA creating the rules for these
ads and finalizing them in 1999.2 This led to consumers doing as
the commercials say and “asking their doctor if drug X is right
for them!”

With the addition of the internet it is very easy

for people to discover new drugs that they can then seek out, as
opposed to doctors being the ones giving out information on
prescription drugs.2
Another important driver to the increasing prescription
costs is the amount of drugs being introduced that are merely
incrementally modified versions of previous drugs.2 This can be
seen by that fact that the amount of new drugs that have new
therapeutic value increased by only 10% from 1995 to 2000 while
the amount of drugs that were just modified versions of older
drugs increased by 81%.2
In an article by the Star Tribune a doctor speaks about how
easy a solution taking a pill for heartburn is as compared to a
change in lifestyle to fix the illness.8 A doctor had even
mentioned that during his residency “I was told it was a quick
and easy answer to everything, and it had no side effects, and
insurance was willing to pay for it."8 Fixing the underlying
problems is the better solution for many patients, but as the
article says people would rather take the path of least
5

resistance, and that comes in pill form.8 The problem lies in the
fact that these drugs have a purpose to cure an illness, but are
rather being used so people can maintain their bad lifestyle
choices.
Furthermore, in the Star Tribune article the focus is on
the over-prescription of drugs by doctors.8 Doctors often give
the person the drug just to see if they improve with no real
medical reason for prescribing it.8 One doctor is quoted as
saying "What's the downside? I might make you feel better. I'm
saving you an invasive test. And if it works, I'm a hero."

The

downside comes twofold. First from the fact that the article
claims that up to 69% of acid-suppressing drugs are for
inappropriate reasons, which means a lot of wasted money that
need not be spent.8 The second is from what is mentioned as the
“Rebound Effect.”

Once someone is on the drug if they stop

taking the drug their acid production system kicks into
overdrive.8

Drug Formularies Explained:
A drug formulary is essentially a categorization of
prescription drugs with each category representing a different
amount that the patient needs to pay before health insurance

6

will cover the remaining amount. This definition applies to both
private health insurance and Medicare part D.

The way a

formulary is set up is well shown through how Medicaid handles
it. A formulary must be established by a pharmacy and
therapeutic (P&T) committee which includes a majority of
practicing physicians and/or pharmacists.5 In developing and
reviewing the formulary, the committee must make clinical
decisions based on “the strength of scientific evidence and
standards of practice” and, when determining which drugs should
be included in the formulary, the committee must consider
whether certain covered drugs provide “therapeutic advantages in
terms of safety and efficacy.”5 While the effectiveness of a drug
is taken into account, the cost seems to be a largest
determining factor as well.
Plan sponsors must inform patients about the formulary
and “appropriate” notice must be given before a drug may be
removed from the formulary or before a drug’s preferred status
is changed.5 This gives the companies a wide range of power to
change how much each drug will cost the patients even if it can
only be done annually.5

An example of this can be show in

Saltzman v. Independence Blue Cross where the drug Plavix was
moved from a preferred tier 2 drug, which appeared on the
formulary, to a tier 3 non-preferred drug, which in this case
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meant any brand name not referred to on the formulary.12 In the
case, the plaintiffs sued with the argument that since there was
no substitute for Plavix on the formulary, removing it from
their formulary they did not meet the “highest level of
coverage” that the contract mentioned the company would take
into account for placing drugs in their formulary.12 The court
found that the contract allowed for them to alter their
formulary, and that at the statement made in the contract was
one of the insurance company’s opinion of the quality of the
plan and not a concrete commitment to include certain drug
coverages.12
Into which tier a drug falls in a formulary depends on the
company, a general overview helps to understand what each tier
of drug means for the patients.
Tier 1 drugs are generally drugs that have since lost their
patent and are now generic drugs.10 All drugs will eventually
find their way down to these lower tiers, since as drugs come
off their patents the cost paid for the drug is no longer
affected by research and development costs.
Tier 2 drugs are generally preferred brand name drugs.
Often this means that the insurance company has bargained a good
price with the company that owns the drug.10 In the absence of
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this bargaining many tier 2 drugs in one companies formulary may
appear as tier 3 drugs in another insurance companies formulary.
Tier 3 drugs are the non-preferred name brand drugs that an
insurance company does not want to encourage people taking.10
Even though drugs in this category are not ones that an
insurance company would prefer their patients to take, it does
not guarantee that a cheaper equivalent exists on a lower tier.
Tier 4 is different from all other tiers.

This tier does

not generally have a maximum co-pay for the drugs, but rather is
based on a percentage of the total retail price.
range between 30 to 70 percent.

This price can

This tier is for the most

expensive drugs on the market. This tier came about in 2003 with
the Medicare Prescription Drug, Improvement, and Modernization
Act of 2003.5

9

Drug Formularies effect on Health Care Costs:
The following graph shows the percentage increase in total
health care costs over the previous years.3
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Annual % Increase of Prescription Drug Costs
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The key point to look at is 2003, where the downturn begins.
This point is important because this is when the Medicare
Prescription Drug, Improvement, and Modernization Act was
implemented.3

This act had two effects that led to this sudden

decline in our every increasing health care costs.
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The first

was the creation of Medicare Part D, which created a formulary
for Medicare usage.5 The second part was the fact that it also
allowed Insurance companies to create the cost cutter that is
tier 4 drugs.1 Before we bring out the party poppers to celebrate
this marked slowdown in the cost of health care, there is
something else to consider. This method did wonders when it
comes to reducing prescription drug expenditures, the moral
question that then must be then asked is how did this change
affect the quality of the care given to the patients.
The New York Times wrote an article discussing the affect
this change had on patients on an individual level.11 The first
story they tell is of women named Robin Steinward who has
multiple sclerosis.11

Prior to the creation of tier 4 in drug

formularies, her co-payment for Copaxone was 20 dollars a
month.11 After the change, her bill jumped to 325 dollars a
month, which is equal to 25% of the drugs cost.11

Suddenly, she

now questions that with the additional cost will she be able to
pay for her son’s tuition or pay for her own retirement?11 While
the story is heartbreaking, the fact that she is continuing to
get the drug means that her quality of care has not gone down.
Another situation mentioned in the article however is troubling
when it comes to quality.11 Mr. Banning is in need of a drug
called Sprycel, which costs $13,500 for a 90-day supply.11 With
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the new drug tier system he is currently not on the drug despite
the fact that he should be on it for the remainder of his life.11
The reason this story is more troubling is the fact that Mr.
Banning isn’t receiving quality care any longer, he is in fact
not receiving any care at all.

The question that then must be

asked is, which situation is the normal as of 2003?
following graph answers just that question.3
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The
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Annual % Increase of Out of Pocket on
Prescription Drugs
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To interpret this graph we must ask what would happen to out of
pocket expenses if patients continued to receive the same level
of care? What would happen to out of pocket expenses if people
no longer could afford to obtain prescription drugs?3 If the
benefit to the patients had remained the same it would mean that
a majority of people would act like Robin Steinward, who made
sacrifices in her own life to continue to pay for her medication
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which should cause an increase in the amount of out of pocket
expenditures.

If people were stopping treatment due to the

increased cost of the drugs, we would expect out of pocket
expenses to decrease since where before they had obtained the
drug after paying the co-pay, now they would simply forego
getting treatment and their out of pocket expenditures would be
at zero.
As we see in the graph above, the truth of the matter is
out of pocket expenses decreased after 2003.

Since we have this

decrease, it is possible the reasons are for those expressed in
the prior paragraph.

Those who cannot afford to pay the high

cost of tier 4 prescription drugs simply drop off leaving only
those who pay less out of pocket to be included in the data.
Looking at the graph in another context could also further
show that even though out of pocket expenditures have decreased,
it has not been by a noteworthy amount.
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This graph show where the money comes for that actually pays for
prescription drugs.3 While the graph showing out of pocket
expenses annual change show a very large decline, this graph
more shows that the percentage of out of pockets hasn’t changed
by a large amount.

Formulary Solution:
When measured up to the two objectives set forth at the
beginning of the paper, the current drug formularies, in
particular the drugs classified at tier 4 or higher, sacrifices
the patients that cost the most to the health insurance industry
in favor of a more sustainable system for the rest of the
population.

This is not to say that I am not impressed by the
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marked change in how quickly the spending on prescriptions drugs
have dropped.

The problem is that after examining all the

problems that lead to the increasing costs, there are safeguards
already in place but not in use,that could be used to prevent
drugs from being unavailable to anyone through high tier
formularies.
The method which is already currently implemented, but is
mostly a guard dog with no teeth is the “The Nondiscrimination
Criterion.” This allows for a formulary to be rejected if it has
a discriminatory effect of trying to drive away those who are
ill.9

The reason this has no bite to it is the fact that the

rules are so vague that it leaves a very large grey area as to
what is and what is not permitted.9

So long as you stay within

the most basic guidelines most levels of percentage based copays are allowed.9 The way in which this could be fixed would be
using the data collected since the introduction of The Medicare
Prescription Drug, Improvement, and Modernization Act of 2003 to
see if patients are being pushed out of the market.

At the

introduction of the Act vague rules could be expected as they
had nothing to go on as to what would and what would not
constitute abuse. Since then, even with the small amount of data
examined that if enough people are unable to obtain drug that
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are in tier 4 such that it has a large effect on out-of-pocket
expenses it is worth looking into.

Solution - Drug tier reform:
When trying to come with a solution that will directly
affect the way the pricing system for prescription drugs will
work there are two path we can take.

I like to call these

paths, the path of Revolution and the path of Evolution.
The path of Revolution would be to create a solution that
complete destroys the current pricing scheme in an attempt to
replace it with a more efficient one. This would be admirable as
a long term goal, it would be nearly impossible to create one
that could be effectively implemented.

Implementing it would

require Congress to agree on a solution.
The path of Evolution would be to build upon what is
already in place.

This is a much simpler solution since

leverages much of what already exists and attempt to isolate the
flaws within the current system.

This seems to be a more

reasonable approach that my solution would fall under.
My solution is simple in form at least, and that is for
each drug to be able to exist across multiple tiers depending on
the purpose. To understand we must refer back to the article by
17

Maura Lerner of the Star Tribune which discusses overprescribing and improperly prescribing a drug called Nexium for
GERD (gastro esophageal reflux disease) despite the fact that
patients had not been diagnosed with GERD.8 The drug was highly
advertised and as a result made it one of the highest selling
prescription pills in the country.8

Now, this is not to say that

the drug was not useful since upon its release it was hailed as
a miracle drug that boasted a 90% success rate of resolving
GERD.8

The problem arises in the fact that the healing was

originally planned over an 8 week period, and once the drug
received FDA approval doctors were prescribing it for a lot
longer.8 Some people remained on the drug for years and are
likely going to be on it for the rest of their lives.8 To get
someone off the drug they need to be weaned.8 This is due to the
rebound effect mentioned earlier; to take someone who has grown
accustomed to the drug, off of the drug, can result in a sudden
surge of acid production.8

The drug is also prescribed to many

people who had not been diagnosed with GERD and whose heartburn
doesn’t warrant the possible side effects of Nexium.8

The end

result of all this is many people spending unnecessary money of
their own along with the money of health insurance companies on
a drug that is given as a knee jerk reaction to heartburn.
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Currently in formularies, the effectiveness of a drug is
taken in account in its placement on the list.5 However, Nexium
could be seen as defying that purpose, because its effectiveness
is based on the shorter treatment cycles for treating GERD.7 This
is where my solution comes as previously stated it is to alter
the current tier system to make it so a single drug can actually
appear across multiple drug tiers depending on why they were
prescribed.

An example of what I mean is that currently in many

formularies Nexium is considered a tier 3 drug, but that tier
should be based on the fact that they have been diagnosed for
GERD, and that they are only taking it for a limited time as is
necessary to cure the illness.10 Should they want to take the
drug for simple heartburn that could be solved without Nexium,
the drug would be in a higher tier so that they would pay a
premium. This gives an incentive to prescribe drugs for a
specific illness as opposed to a catchall approach so that the
patient can get a lower cost on the drugs.

A catchall approach

might look at the symptom of heart burn and say that while many
things cause it, varying from eating too late at night to being
afflicted with GERD, the drug Nexium would have a positive
effect either way.

The problem with that is that side effects,

the duration at which the patient remains on the drug, and the
alternatives will vary depending on what the patient actually
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has.

The incentive is to get away from sweeping prescriptions

and more towards directed solutions.
Even if a patient forgoes an invasive test to just see if
the drugs will improve their condition it will work to better
patient care regardless of whether the drug works or not.

If it

succeeds then you can move towards a diagnosis, since the test
is now more worthwhile with a higher chance of it proving what
is actually the cause of the heartburn.

If the drug does not

help, then you would stop taking the drug, so that even if you
paid a premium it would only be for a short time.

When looking

to how people describe expensive drugs are, they often look to
the annual cost it will put on a patient. If the drug isn’t
helping there wouldn’t be an annual cost since you would not
remain on a drug that had no positive benefit for over a year.
Another benefit to this solution would be that it is selfpolicing.

For example, imagine a Doctor that gives diagnoses

with each prescription so that the patient will get the drug at
the drug’s lowest price.

The doctor would become open to suit

from health insurance companies for lying to obtain cheaper
prices, and they would open themselves up to medical malpractice
if it turns out the phony diagnosis is wrong and their only
reasoning for coming to that diagnosis was to get the patient a
cheaper drug.

So a doctor has an incentive to not defraud the
20

system since if he does, he runs the risk of suit from both the
party he would be trying to help and the party he is defrauding.
Now, there is the opposite danger which is if a doctor
misdiagnosis an illness and is accused of trying to cheat the
system.

The solution would be that for an insurance company to

win they would need to show a trend of diagnosis that can only
have the purpose of defrauding insurance companies.

For a

patient to sue for malpractice would not be burdened with these
problems, since a patient would know whether or not the doctor
is purposely misdiagnosing them which is clearly below the
standard of care.
The next part of the solution that needs to be examined is
how exactly this will lower cost.

The answer is that it depends

on how people react to the solution.

The way the solution

incentives work, we would lower cost by making it unappealing
for people to get prescription drugs if they want it for a
lifestyle purpose as opposed to getting it at a cheaper price
for a necessity purpose.

Lifestyle choice being when an

alternative to taking the drug is changes in things such as
eating habits, exercise, etc.

A necessity purpose would be one

where you have an illness that a prescription drug has the main
purpose of curing such as Nexium curing GERD.

This would result

in a drop in money spent on prescription drugs and lower the
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cost overall.

The other side of the coin is that if this

solution was implemented and all patients simply paid the higher
cost and continued to take the prescription drugs for all
purposes it would have a cost-shifting effect.

This means that

the actually expenditures on prescription drugs would remain the
same, but patients would bear a larger portion of the cost.
This would still be beneficial since the patients that would
make up this increase in patient costs would be people who are
taking the drug for lifestyle purposes, and the health care
system itself would have lower expenses.
The result on cost will likely be somewhere in between
lowered expenditures and cost-shifting onto some patients.

This

result can be seen in a findings brief of an experiment where a
two tiered drug formulary was turned into a three tier drug
formulary.13 The structure for the part of the experiment that is
most similar to what occurred within Medicare part D was a
formulary that originally had a 7 dollar co-payment for all
generic and brand name drugs turned into a three tier system.
This new system had an 8 dollar co-pay for tier 1 generic drugs,
a 15 dollar co-pay for tier 2 preferred drugs, and a 30 dollar
co-pay for tier 3 non-preferred drugs.13 The result was two-fold,
a noticeable switching or stoppage from tier 3 drugs.13 There was
also a marked drop in the cost to the health care plan, but
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accompanied by an increase in the cost onto the employees.

My

solution would avoid the pitfall of increasing the cost on
everyone, to increasing cost mostly to those who are taking
drugs for lifestyle purposes.

Solution – New or Improved?:
As previously stated when discussing what drives up the
cost of prescription drugs I mentioned the types of drugs that
are being created. Only 10% are newly developed drugs, while 81%
are improvements on existing drugs.2 Within the current system of
improved drugs, a drug company is able to market an adjusted
form of a current drug to obtain a new patent and prolong their
monopoly.

The problem arises when you ask the question “How big

an improvement should warrant not letting the drug become
generic?”

To answer this would be difficult especially on a

drug by drug basis.

Since if a drug has a 2% increase in

effectiveness, it would likely look like it hasn’t improved
enough to warrant a new patent.

However, if that drug was a

cancer drug that increased a patient’s survival rate, or the
duration they might live by that amount, suddenly 2% means the
world.
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To effectively lower cost through denial of patents to
slightly improved drugs a general of improvement could not be
imposed since what defines a significant improvement will vary
from drug to drug.

The actual solution would be to give a right

to challenge patents on all improved drugs to private companies.
If the improvement is minimal, it would be worth it for a
generic brand company to challenge a patent to be able to
produce the drug themselves.

It would also give incentive to

drug companies to not strive for a direct percentage point of
improvement, but rather the ability to argue a significant
improvement within their own drug.

This would be a two-fold

benefit since not only would it decrease the number of minutely
improved drugs from getting patents, but the cost of it would be
paid by companies seeking their own best interests.

Conclusion:
By applying this to the current formulary system we achieve
both the objective of health insurance. The system would help to
stifle cost by eliminating much of the knee jerk response to
prescribing drugs without a clear reason, while at the same time
not requiring an entire overhaul of the formulary system.

With

stronger enforcement of the Nondiscrimination Criterion, we
would avoid those who are most sick from being abandoned for the
24

sake of cost. Finally, we can reduce the amount of drugs that
come onto the market that are minor improvements on already
existing drugs. There will still be cost shifting onto some
patients, but it will be spread over people who won’t bear the
cost for long period or people who have alternative solutions,
as opposed to all the costs being shifted to those in need of
the most expensive drugs.

Prior to Medicare Prescription Drug

Improvement and Modernization Act, the cost was spiraling out of
control, and if the patient never has to bear any of the cost
they will never have an incentive to move away from the current
growth of consuming of prescription drugs.
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